Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04071158 · ClinicalTrials.gov registry record · Phase 2
A Study OF A RSV Vaccine When Given Together With Tdap IN Healthy Nonpregnant Women Aged Between 18 TO 49 Years
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 713
- Enrollment target
NCT04071158 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 713 participants.
The verdict
NCT04071158, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 713 participants
- Enrollment target
Study Summary
This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age. This study will evaluate non-inferiority of RSV vaccine when given with Tdap and vice-versa.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV Vaccine
- BIOLOGICAL Tdap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 713 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04071158
The ClinicalTrials.gov registry entry for NCT04071158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 713 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04071158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04071158 about?
NCT04071158 is a clinical study titled "A Study OF A RSV Vaccine When Given Together With Tdap IN Healthy Nonpregnant Women Aged Between 18 TO 49 Years". This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age. This study will evaluate non-inferiority of RSV vaccine when given with Tdap and vice-versa.
What is the current status of trial NCT04071158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 713 participants. The study started on 2019-10-01. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT04071158?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV Vaccine (BIOLOGICAL), Tdap (BIOLOGICAL).
Who is sponsoring clinical trial NCT04071158?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.